Allogene Therapeutics, Inc. Payments to Acquire Investments
Allogene Therapeutics, Inc. (ALLO) reported Payments to Acquire Investments of $285.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-12
- Allogene Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $183.72M, a 1751.84% increase year-over-year.
- Allogene Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $101.69M, a 102.48% increase year-over-year.
- Allogene Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $28.38M, a 39.59% decline year-over-year.
- Allogene Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $49.73M, a 73.93% decline year-over-year.
- Allogene Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $138.26M, a 61.75% decline from fiscal 2024.
- Allogene Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $361.48M, a 17.59% decline from fiscal 2023.
- Allogene Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $438.63M, a 76.79% increase from fiscal 2022.
- Allogene Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $248.11M, a 52.79% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 1 month | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $183.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $285.42M 10-Q · filed 2026-08-12 | $313.79M derived: sum of 3 quarters · filed 2026-08-12 | $363.53M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $101.69M 10-Q · filed 2026-05-13 | $130.07M derived: sum of 2 quarters · filed 2026-05-13 | $179.81M derived: sum of 3 quarters · filed 2026-05-13 | $189.73M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $28.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $78.11M derived: sum of 2 quarters · filed 2026-03-12 | $88.03M derived: sum of 3 quarters · filed 2026-08-12 | $138.26M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $49.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $59.66M derived: sum of 2 quarters · filed 2026-08-12 | $109.88M 10-Q · filed 2025-11-06 | $156.85M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $9.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $60.15M 10-Q · filed 2026-08-12 | $107.12M derived: sum of 3 quarters · filed 2026-08-12 | $297.88M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $50.23M 10-Q · filed 2026-05-13 | $97.20M derived: sum of 2 quarters · filed 2026-05-13 | $287.96M derived: sum of 3 quarters · filed 2026-05-13 | $330.57M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $46.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $237.74M derived: sum of 2 quarters · filed 2026-03-12 | $280.34M derived: sum of 3 quarters · filed 2026-03-12 | $361.48M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $190.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $233.37M derived: sum of 2 quarters · filed 2025-11-06 | $314.50M 10-Q · filed 2025-11-06 | $383.20M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $42.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $123.74M 10-Q · filed 2025-08-13 | $192.44M derived: sum of 3 quarters · filed 2025-08-13 | $391.85M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $81.13M 10-Q · filed 2025-05-13 | $149.83M derived: sum of 2 quarters · filed 2025-05-13 | $349.25M derived: sum of 3 quarters · filed 2025-05-13 | $484.67M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $68.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $268.12M derived: sum of 2 quarters · filed 2025-03-13 | $403.54M derived: sum of 3 quarters · filed 2025-03-13 | $438.63M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $199.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $334.83M derived: sum of 2 quarters · filed 2024-11-07 | $369.93M 10-Q · filed 2024-11-07 | $417.72M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $135.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $170.51M 10-Q · filed 2024-08-07 | $218.31M derived: sum of 3 quarters · filed 2024-08-07 | $267.76M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $35.09M 10-Q · filed 2024-05-13 | $82.89M derived: sum of 2 quarters · filed 2024-05-13 | $132.34M derived: sum of 3 quarters · filed 2024-05-13 | $194.05M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $47.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $97.25M derived: sum of 2 quarters · filed 2024-03-14 | $158.95M derived: sum of 3 quarters · filed 2024-03-14 | $248.11M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $49.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $111.16M derived: sum of 2 quarters · filed 2023-11-02 | $200.32M 10-Q · filed 2023-11-02 | $251.10M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $61.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $150.86M 10-Q · filed 2023-08-02 | $201.65M derived: sum of 3 quarters · filed 2024-03-14 | $347.07M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $89.16M 10-Q · filed 2023-05-03 | $139.94M derived: sum of 2 quarters · filed 2024-03-14 | $285.36M derived: sum of 3 quarters · filed 2024-03-14 | $465.69M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $50.78M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $196.20M derived: sum of 2 quarters · filed 2024-03-14 | $376.53M derived: sum of 3 quarters · filed 2024-03-14 | $525.58M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $145.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $325.75M derived: sum of 2 quarters · filed 2022-11-02 | $474.80M 10-Q · filed 2022-11-02 | $656.96M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $180.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $329.38M 10-Q · filed 2022-08-09 | $511.54M derived: sum of 3 quarters · filed 2024-03-14 | $724.79M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $149.05M 10-Q · filed 2022-05-04 | $331.21M derived: sum of 2 quarters · filed 2024-03-14 | $544.46M derived: sum of 3 quarters · filed 2024-03-14 | $1.06B derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $182.16M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $395.41M derived: sum of 2 quarters · filed 2024-03-14 | $914.58M derived: sum of 3 quarters · filed 2024-03-14 | $1.04B 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $213.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $732.42M derived: sum of 2 quarters · filed 2021-11-04 | $855.43M 10-Q · filed 2021-11-04 | $945.13M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $519.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $642.18M 10-Q · filed 2021-08-04 | $731.88M derived: sum of 3 quarters · filed 2022-02-23 | $793.05M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $123.02M 10-Q · filed 2021-05-05 | $212.71M derived: sum of 2 quarters · filed 2022-02-23 | $273.89M derived: sum of 3 quarters · filed 2022-02-23 | $323.25M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $89.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $150.87M derived: sum of 2 quarters · filed 2022-02-23 | $200.23M derived: sum of 3 quarters · filed 2022-02-23 | $252.63M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $61.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $110.53M derived: sum of 2 quarters · filed 2020-11-04 | $162.93M 10-Q · filed 2020-11-04 | $496.84M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $49.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $101.76M 10-Q · filed 2020-08-05 | $435.66M derived: sum of 3 quarters · filed 2021-02-25 | $751.06M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $52.40M 10-Q · filed 2020-05-06 | $386.31M derived: sum of 2 quarters · filed 2021-02-25 | $701.70M derived: sum of 3 quarters · filed 2021-02-25 | $701.70M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $333.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $649.31M derived: sum of 2 quarters · filed 2021-02-25 | $649.31M derived: sum of 3 quarters · filed 2021-02-25 | $649.31M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $315.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $315.40M derived: sum of 2 quarters · filed 2019-11-05 | $315.40M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |